What if you could diagnose and treat cancer at the same time? That’s the promise of theranostics – a groundbreaking approach that personalizes care down to a molecular level. Steve Wozniak, BS, CNMT, PET, associate director of molecular imaging & theranostics at 210 PET Imaging and 210 Theranostics breaks down how it works, what it means for cancer patients and what’s on the horizon in this evolving field.
Selected Podcast
Theranostiscs: A New Approach to Cancer Diagnosis and Treatment
Featured Speaker:
Steven Wozniak, BS, CNMT, PET
Steven Wozniak is the associate director of molecular imaging and theranostics at 210 PET Imaging and 210 Theranostics – a joint venture between Raleigh Radiology and WakeMed. With over 35 years of experience in nuclear medicine and molecular imaging, and more than 20 years in PET, he is board-certified in both specialties. Steven has served on the Intersocietal Accreditation Commision of Nuclear Medicine Laboraties (ICANL) board, the Nuclear Medicine Technology Certification Board (NMTCB) board of directors and held leadership roles within the Society of Nuclear Medicine and Molecular Imaging (SNMMI) a all levels. His career was inspired by his own experience as theranostics patient in the late 1980s, igniting a lifelong passion for molecular imaging and patient care.